Implications of hypertrophic cardiomyopathy transmitted by sperm donation

JAMA

Volumn 302, Issue 15, 2009, Pages 1681-1684

  Maron, Barry J ^a   Lesser, John R ^a   Schiller, Nelson B ^c   Harris, Kevin M ^a   Brown, Colleen ^c   Rehm, Heidi L ^b  

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYOSIN HEAVY CHAIN BETA; CARDIAC MYOSIN; MYH7 PROTEIN, HUMAN; MYOSIN HEAVY CHAIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CASE REPORT; CHILD; CLINICAL ASSESSMENT; COMMUNITY; CONCEPTION; DEATH; DISEASE COURSE; DISEASE TRANSMISSION; DONOR; ELECTROCARDIOGRAM; FERTILIZATION; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; GENETIC DISORDER; HEALTH CARE FACILITY; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INCIDENCE; INHERITANCE; MALE; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGENY; RECIPIENT; SCREENING; SPERM DONOR; SUDDEN DEATH; SURVIVAL; UNITED STATES; ADOLESCENT; ARTIFICIAL INSEMINATION; DONOR SELECTION; ELECTROCARDIOGRAPHY; FEMALE; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; MISSENSE MUTATION; PEDIGREE; PRESCHOOL CHILD; SPERMATOZOON; STANDARD;

ADOLESCENT; CARDIAC MYOSINS; CARDIOMYOPATHY, HYPERTROPHIC; CHILD; CHILD, PRESCHOOL; DONOR SELECTION; ELECTROCARDIOGRAPHY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; INSEMINATION, ARTIFICIAL, HETEROLOGOUS; MALE; MUTATION, MISSENSE; MYOSIN HEAVY CHAINS; PEDIGREE; PHENOTYPE; SPERM BANKS; SPERMATOZOA; TISSUE DONORS; YOUNG ADULT;

EID: 70350741312     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.1507     Document Type: Article

References (17)

1. US Department of Health and Human Services; US Food and Drug Administration; Center for Biologics Evaluation and Research. Guidelance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue- Based Products (HCT/Ps), August 27, 2007. http://www.fda.gov/BiologicsBloodVaccines / GuidanceComplianceRegulatoryInformation /Guidances/Tissue/ucm073964.htm. Accessed September 2, 2009.
2. Practice Committee of American Society for Reproductive Medicine; Practice Committee of Society for Assisted Reproductive Technology. 2008 Guidelines for gamete and embryo donation: a Practice Committee report. Fertil Steril. 2008;90(5)(5 suppl): S30-S44.
3. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42(9):1687-1713.
4. Alcalai R, Seidman JG, Seidman CE. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. J Cardiovasc Electrophysiol. 2008;19(1):104-110.
5. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342(24):1778-1785. (Pubitemid 30390237)
6. Maron BJ, Spirito P, Shen W-K, et al. Implantable cardioverter- defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298(4):405-412. (Pubitemid 47124061)
7. Maron BJ, Tajik AJ, Ruttenberg HD, et al. Hypertrophic cardiomyopathy in infants: clinical features and natural history. Circulation. 1982;65(1):7-17.
8. Rickers C, Wilke NM, Jerosch-Herold M, et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation. 2005;112(6):855-861. (Pubitemid 41170072)
9. Wirojanan J, Angkustsiri K, Tassone F, Gane LW, Hagerman RJ. A girl with fragile X premutation from sperm donation. Am J Med Genet A. 2008;146(7):888-892.
10. Maron BJ, Gardin JM, Flack JM, Gidding SS, Bild D. Assessment of the prevalence of hypertrophic cardiomyopathy in a general population of young adults: Echocardiographic analysis of 4111 subjects in the CARDIA Study: Coronary Artery Risk Development In (young) Adults. Circulation. 1995;92(4):785-789.
11. Maron MS, Appelbaum E, Harrigan CJ, et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy [published online ahead of print June 23, 2008]. Circ Heart Fail. 2008;1:184-191. doi:10.1161/circheartfailure.108.768119.
12. Gazvani R, Hamilton MPR, Simpson SA, Templeton A. New challenges for gamete donation programmes: changes in guidelines are needed. Hum Fertil. 2002;5(4):183-184. (Pubitemid 36277745)
13. Van Driest SL, Ommen SR, Tajik J, Gersh BJ, Ackerman MJ. Yield of genetic testing in hypertrophic cardiomyopathy. Mayo Clin Proc. 2005;80(6):739-744.
14. Maron BJ, Niimura H, Casey SA, et al. Development of left ventricular hypertrophy in adults with hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C mutations. J Am Coll Cardiol. 2001;38(2):315-321. (Pubitemid 32721755)
15. Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med. 1998;339(6):364-369. (Pubitemid 28363798)
16. Myerburg RJ, Vetter VL. Electrocardiograms should be included in preparticipation screening of athletes. Circulation. 2007;116(22):2616-2626.
17. Miller MD, Porter CB, Ackerman MJ. Diagnostic accuracy of screening electrocardiograms in long QT syndrome. Pediatrics. 2001;108(1):8-12. (Pubitemid 32594775)